Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 3/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.70 |
| ▸ | RELA | Q04206 | 3/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.63 |
| ▸ | F3 | P13726 | 5/20 | 0.63 |
| ▸ | PNLIP | P16233 | 1/20 | 0.63 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.63 |
| ▸ | NOS2 | P35228 | 1/20 | 0.63 |
| ▸ | CES2 | O00748 | 2/20 | 0.63 |
| ▸ | CES1 | P23141 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | OXTR | P30559 | 1/20 | 0.61 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.61 |
| ▸ | CD81 | P60033 | 1/20 | 0.61 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Echinocystate SCHEMBL17030530 | 0.86 | F3 (0.82) | RELAPTPN1F3PTPN2CES1 | |
| SCHEMBL18687848 | 0.84 | PTPN1 (0.81) | NFKB1NFKB2RELAPTPN1F3 | |
| SCHEMBL16152971 | 0.84 | PTPN1 (0.81) | NFKB1NFKB2RELAPTPN1F3 | |
| SCHEMBL30278367 | 0.84 | PTPN1 (0.81) | NFKB1NFKB2RELAPTPN1F3 | |
| SCHEMBL17131714 | 0.84 | F3 (0.69) | RELAPTPN1F3PTPN2CES1 | |
| SCHEMBL18712772 | 0.83 | F3 (0.66) | RELAPTPN1F3PTPN2CES1 | |
| SCHEMBL17131713 | 0.83 | PTPN1 (0.64) | NFKB1NFKB2RELAPTPN1F3 | |
| SCHEMBL6379039 | 0.81 | NFKB1 (0.87) | NFKB1NFKB2RELAPTPN1F3 | |
| SCHEMBL23802406 | 0.81 | PTPN1 (0.66) | PTPN1F3CYP3A4MAPK1OXTR | |
| SCHEMBL19976704 | 0.80 | F3 (0.59) | NFKB1NFKB2RELAPTPN1F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920088-B2 | Triterpene derivative and its anti-influenza use | University of Macao (CN) | 2018-03-20 | — | — | US | disclosed |
| US-9920088-B2 | Triterpene derivative and its anti-influenza use | University of Macao (CN) | 2018-03-20 | — | — | US | disclosed |
| US-20150274766-A1 | Triterpene Derivative and Its Anti-Influenza Use | PEKING UNIVERSITY (CN) | 2015-10-01 | — | — | US | disclosed |
| US-20150274766-A1 | Triterpene Derivative and Its Anti-Influenza Use | PEKING UNIVERSITY (CN) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274766-A1 | Triterpene Derivative and Its Anti-Influenza Use | HAVCR2, MAVS, IRF3 | NFKB1 287/4885NFKB2 315/4885RELA 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.